The Associated Press reports, Swiss drugmaker Roche Holding AG announced it is paying $230 million to take over Anadys Pharmaceuticals Inc., a U.S.-based specialist in the development of hepatitis C treatments. The offer amounts to $3.70 per share, a premium of more than 250 percent on Anadys''s closing price Friday, Roche said. The board of San Diego-based Anadys approved the deal, which analysts said could boost the company''s chances of getting approval for Setrobuvir, an oral drug currently being tested for treatment of chronic infections with hepatitis C virus, or HCV. Roche said the acquisition would boost its portfolio of hepatitis C drugs, which include Pegasys and Copegus. Last week, the Basel-based company reported third-quarter sales of 9.82 billion Swiss francs ($10.98 billion).